Novartis has a third FDA-approved indication for its oral therapy for complement-mediated diseases – Fabhalta – after getting a green light in ultra-rare kidney disease C3 glomerulopathy (C3G).

C3G generally affects adolescents and young adults and can lead to kidney failure and the need for a transplant in around half of all patients within 10 years, with the disease in some cases ...

When harmful bacteria or other microorganisms invade the body, neutrophils, a type of white blood cell, are one of the first immune cells to respond. They release powerful weapons to trap and kill ...

Phase 3 results revealed Monday led shares to surge and should yield an approval application in IgA nephropathy, a ...

Zakk Coomes discovered last week that he is in kidney failure. But he is relying on his faith to carry him through as his ...

In a world first, Canadian scientists at the CRCHUM, the hospital research center affiliated with Université de Montréal, ...

With updated Phase I/Ib data in hand, Arcus will launch a Phase III trial as it aims to compete with Merck, whose drug ...

Women, older adults, and low-income countries are impacted most; researchers call for urgent public health interventions.

A phase 1b study of HC-7366 plus Welireg for advanced clear cell renal cell carcinoma has completed the dose escalation ...

Based on genome-wide association study data from 2.2 million individuals, a functional prioritization scorecard integrates classical omics with allele-specific gene expression, chromatin ...

A variant in the IL-7 gene may predict which patients with kidney cancer are more likely to experience side effects from immunotherapy.

Many bleaching creams contain harmful chemicals like steroids, which can lead to skin thinning and other long-term health issues. [Courtesy] Every time Caroline* (not her real name) looked in the ...